Skip to main content
. Author manuscript; available in PMC: 2017 Apr 27.
Published in final edited form as: Lancet Oncol. 2016 Apr 4;17(5):651–662. doi: 10.1016/S1470-2045(16)00078-4

Table 2.

FOLFIRINOX (n=6) FOLFIRINOX plus PF-04136309 (n=39)
Grade 1 or 2 Grade 3 Grade 4 Grade 5 Grade 1 or 2 Grade 3 Grade 4 Grade 5
Hematologic
Neutropenia 0 2 (33%) 4 (67%) 0 2 (5%) 15 (38%) 12 (31%) 0
Febrile neutropenia 0 0 1 (17%) 0 0 5 (13%) 2 (5%) 0
Anemia 4 (67%) 2 (33%) 0 0 34 (87%) 3 (8%) 0 0
Lymphopenia 2 (33%) 1 (17%) 0 0 20 (51%) 4 (10%) 0 0
Thrombocytopenia 4 (67%) 0 0 0 19 (49%) 1 (3%) 1 (3%) 0
Non-Hematologic
Nausea 3 (50%) 0 0 0 23 (59%) 1 (3%) 0 0
Vomiting 2 (33%) 0 0 0 13 (33%) 1 (3%) 0 0
Diarrhea 4 (67%) 2 (33%) 0 0 19 (49%) 6 (15%) 0 0
Mucositis 3 (50%) 0 0 0 16 (41%) 1 (3%) 0 0
Alopecia 4 (67%) 0 0 0 28 (72%) 0 0 0
Peripheral neuropathy 1 (17%) 0 0 0 25 (64%) 0 0 0
Hypoalbuminemia 4 (67%) 1 (17%) 0 0 25 (64%) 2 (5%) 0 0
Hypokalemia 1 (17%) 3 (50%) 0 0 17 (44%) 5 (13%) 2 (5%) 0
ELEVATED ASPARTATE Aminotransferase 2 (33%) 0 0 0 12 (31%) 2 (5%) 0 0